Freezing tumors may boost immunotherapy in stubborn melanoma

NCT ID NCT05779423

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether freezing part of a growing tumor (cryoablation) can help two immunotherapy drugs, ipilimumab and nivolumab, work better in people with advanced melanoma that has stopped responding to initial treatment. About 37 adults whose melanoma is growing despite prior immunotherapy will receive the drug combo plus the freezing procedure. The goal is to see if this combination can shrink tumors or keep them stable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Ipilimumab (Yervoy) and nivolumab (Opdivo) combined with cryoablation (freezing the tumor)

What this could lead to

If successful, this approach could offer a new treatment option for people with advanced melanoma that stops responding to standard immunotherapy, potentially controlling the disease longer.

What could go wrong

This is a small, early-phase study (37 participants) testing a combination of existing drugs plus a procedure. It may not work for everyone, and side effects from the drugs or procedure could be serious.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma skin cancer skin neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Massachusetts General Hospital Cancer Center

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact